Tango Therapeutics, Inc. - Common Stock (NQ:TNGX)

22.12 +0.22 (+1.00%)

Delayed Quote Updated: 1:38 PM EDT, Oct 7, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Tango Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >

These stocks are moving in today's session ↗

June 08, 2026

Via Chartmill

Top stock movements in today's session. ↗

June 08, 2026

Via Chartmill

These stocks are gapping in today's session ↗

June 08, 2026

Via Chartmill

Monday's pre-market session: top gainers and losers ↗

June 08, 2026

Via Chartmill

Earnings Scheduled For November 4, 2025 ↗

November 04, 2025

Via Benzinga

A Peek at Tango Therapeutics's Future Earnings ↗

November 03, 2025

Via Benzinga

Earnings Scheduled For August 5, 2025 ↗

August 05, 2025

Via Benzinga

Tango Therapeutics Stock Is Up 840%, and This Fund Just Disclosed Buying $164 Million More ↗

May 29, 2026

This biotechnology firm advances targeted cancer therapies, leveraging genetic insights and strategic partnerships in oncology.

Via The Motley Fool

Acuta Capital Sells 56% of Ocular Therapeutix Shares in Q1 ↗

May 26, 2026

Ocular Therapeutix delivers FDA-approved eye therapies and devices, supported by a pipeline targeting multiple ocular diseases.

Via The Motley Fool

Topics Regulatory Compliance Stocks

Boxer Capital’s $18 Million Corvus Pharma Bet Signals Confidence in This Biotech’s Next Phase ↗

May 17, 2026

Corvus Pharmaceuticals develops immuno-oncology therapies, advancing clinical candidates for cancer and immune-related conditions.

Via The Motley Fool

Topics Regulatory Compliance

Why One Healthcare Fund Increased Its Kodiak Sciences Stake Amid an Eye-Popping Rally ↗

May 17, 2026

This clinical-stage biotech develops innovative retinal disease therapies, with its lead candidate advancing through late-stage trials.

Via The Motley Fool

Topics Regulatory Compliance

Vir Biotechnology Stock Has Doubled This Past Year. One Fund Just Bought 1.2 Million Shares ↗

May 17, 2026

Vir Biotechnology develops antibody and RNA-based therapies for infectious diseases, leveraging partnerships and a robust clinical pipeline.

Via The Motley Fool

Acuta Capital Bet on Erasca (ERAS) and Targeted Cancer Treatments With a 354,575 Share Buy ↗

May 16, 2026

This San Diego biotech develops targeted therapies for RAS/MAPK-driven cancers, advancing several clinical candidates in oncology.

Via The Motley Fool

Topics Regulatory Compliance

Tango Therapeutics President Sells 27,000 Shares for $572,000 as Share Price Skyrockets ↗

April 08, 2026

This precision oncology developer reported a notable insider sale during a period of robust share price gains.

Via The Motley Fool

Topics Regulatory Compliance

Tango Therapeutics Insider Sells $304,000 in Stock Amid a 36% Single-Day Surge ↗

March 30, 2026

This clinical-stage biotech focused on targeted cancer therapies reported a notable insider sale.

Via The Motley Fool

Topics Regulatory Compliance

Is Relay Therapeutics a Buy in 2026? One Institutional Investor Just Made a $6 Million Bet. ↗

March 19, 2026

Relay Therapeutics develops precision oncology medicines using proprietary computational modeling and strategic industry partnerships.

Via The Motley Fool

Nextech Trims Kymera at a Recent High — think Foolishly before acting. ↗

March 19, 2026

Kymera Therapeutics develops targeted protein degradation therapies for immunology and oncology, advancing a diversified clinical pipeline.

Via The Motley Fool

Topics Regulatory Compliance

Investment Firm Doubles Down on Biotech Stock, Adds 386,000 Shares, According to Recent SEC Filing ↗

March 09, 2026

This clinical-stage biotech targets retinal diseases with late-stage drug candidates and a focused pipeline in ophthalmology.

Via The Motley Fool

Topics Regulatory Compliance

Investment Manager Loads Up on CELC Stock, Adds 135,000 Shares, According to Latest SEC Filing ↗

March 06, 2026

This clinical-stage biotech develops precision oncology therapies and diagnostics targeting unmet needs in breast and ovarian cancer.

Via The Motley Fool

Topics Regulatory Compliance

Investment Firm Builds Position in TERN Stock, According to Recent SEC Filing ↗

March 05, 2026

This clinical-stage biotech develops small-molecule therapies for liver and metabolic diseases, targeting unmet needs in NASH and obesity.

Via The Motley Fool

Topics Regulatory Compliance

Investment Firm Bets Big on TNGX Stock With $9.5 Million Purchase, According to Recent SEC Filing ↗

March 04, 2026

This clinical-stage biotech develops targeted cancer therapies, leveraging strategic partnerships and a differentiated oncology pipeline.

Via The Motley Fool

Topics Regulatory Compliance

The $20 Billion Question: Revolution Medicines Surges as Big Pharma Circles the Pan-RAS Leader

January 08, 2026

The first week of 2026 has set the biotech sector ablaze, with Revolution Medicines (NASDAQ: RVMD) finding itself at the epicenter of a high-stakes acquisition tug-of-war. Shares of the Redwood...

Via MarketMinute

Topics Intellectual Property

TANGO THERAPEUTICS INC (NASDAQ:TNGX) Posts Strong Q3 Earnings Beat Amid Mixed Market Reaction ↗

November 04, 2025

Tango Therapeutics (TNGX) reported a strong Q3, beating revenue and EPS estimates. Despite the earnings beat, the stock saw mixed market reaction.

Via Chartmill

Topics Earnings

Is Tango Therapeutics Stock a Buy, Sell, or Hold After Major Shareholder Third Rock Ventures Sold Nearly Half a Million Shares? ↗

October 31, 2025

Is Tango Therapeutics Stock a Buy, Sell, or Hold After Major Shareholder Third Rock Ventures Sold Nearly Half a Million Shares?

Via The Motley Fool

Topics Regulatory Compliance

Tango Therapeutics Touts Encouraging Data From Early-Stage Cancer Trial, Raises Capital To Fund Advancement ↗

October 23, 2025

Tango Therapeutics Inc. (NASDAQ:TNGX) revealed data from its ongoing Phase 1/2 study of vopimetostat (TNG462) in patients with MTAP-deleted cancers.

Via Benzinga

Wondering what's happening in today's pre-market session? ↗

October 23, 2025

Discover the top movers in Thursday's pre-market session and stay informed about market dynamics.

Via Chartmill

Tango Therapeutics Stock Soars Pre-Market On $225M Financing, Positive Study Data For Cancer Therapy ↗

October 23, 2025

CEO Barbara Weber said that across the 16 cancer types enrolled in the trial, the objective response rate (ORR) was 27% in patients with a median follow-up of 9.4 months.

Via Stocktwits

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

October 23, 2025

Via Benzinga

Tango (TNGX) Q2 Revenue Drops 52% ↗

August 05, 2025

Via The Motley Fool

Topics Intellectual Property

Tango Therapeutics Inc (NASDAQ:TNGX) Reports Q2 2025 Earnings: Revenue Misses, EPS Meets Expectations Amid Clinical Progress ↗

August 05, 2025

Tango Therapeutics (TNGX) reported Q2 2025 revenue below estimates but met EPS expectations, causing a 2.4% pre-market dip. Clinical progress in oncology trials remains a key focus.

Via Chartmill

< Previous 1 2 3 4 5 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.